Cellvizio by Mauna Kea Technologies

08/13/2025

How is accuracy in detection being redefined?

Our own Daryl Donatelli answers this in his new byline via Medical Device News Magazine: "See Beyond the Surface: How Redefines Accuracy for Detecting and Treating Cancers." This comes at an exciting time as we offer a huge congratulations to Daryl on his recent promotion to President, U.S. & Head of Global Marketing at Cellvizio by Mauna Kea Technologies!

Discover how Cellvizio® enhances accuracy in cancer care. Insights from Daryl C. Donatelli, MBA, President of Mauna Kea Technologies.

08/12/2025

We're thrilled to announce the promotion of Daryl Donatelli to President, U.S. & Head of Global Marketing at Cellvizio by Mauna Kea Technologies!

Over his 6+ years with our team, Daryl has consistently demonstrated exceptional leadership across multiple commercial initiatives. In this new role, he will spearhead continued growth in our largest market while strengthening our global brand and deepening partnerships within the community.

Please join us in congratulating Daryl on this well-deserved promotion!

08/05/2025

We want to re-share our congratulations to the team at Stanford Health Care for completing their 100th case with in under six months.

This achievement offers new hope for patients with food-related symptoms, providing personalized insights by revealing cell-level food reactions in real time. We are proud to partner with the pioneering team of Drs. Linda Nguyen, Laura A. Pace, and Sean Spencer.

07/29/2025

Yesterday we reported our sales and revenue for the second quarter and half year ended June 30, 2025. H1 results show accelerated U.S. sales growth of +23% in the second quarter, record sales force productivity driven by strong system and probe sales in our indication, and renewed commercial momentum with the signing of three new U.S. accounts. These results reflect the resilience of our business model and our commitment to achieving sustainable growth and profitability.

See the details in the press release: https://hubs.la/Q03zlz260

07/24/2025

Exciting News: We're expanding to Australia! Today we announce we are officially entering the Australian market through a new exclusive distribution agreement with Endotherapeutics, a premier distributor of cutting-edge medical devices.

This strategic partnership is a key milestone in our international expansion. Together, we will bring this innovative technology to Australian physicians, enabling them to better characterize and identify the causes of food-related symptoms.

Read the full PR: https://hubs.la/Q03yPMXh0

Queensland Health

07/21/2025

Building the future of diagnosis, one innovation at a time. Today, we are proud to announce a major expansion of our intellectual property with the grant of our 14th U.S. patent for !

This patent protects our work in real-time AI enhancement, strengthening the crucial interface between doctors and machines. This achievement follows our recent AI breakthrough in pancreatic cancer risk stratification, solidifying our platform as the nexus of innovation in the field. We’re not just developing technology; we’re building an ecosystem for partners to create life-saving AI applications. The future is collaborative.

Learn more about this latest advancement: https://hubs.la/Q03y4YsW0

07/17/2025

Advance your skills in procedures on July 24! Join the Endoscopy On Air Americas live-virtual Hepato-Pancreatico-Biliary (HPB) Course where a EUS-nCLE pancreatic cyst case will be observed. Learn the latest endoscopic techniques from world-renowned experts through live cases and commentary.

Register today: https://hubs.la/Q03xGC0N0

07/15/2025

Big news in ! We’re thrilled to congratulate the team at Stanford Health Care for completing their 100th case using in under 6 months. This milestone is hopeful for patients with food-related symptoms, providing personalized insights by revealing cell-level reactions to food in real time.

Led by Drs. Linda Nguyen, Laura A Pace, and Sean Spencer, is revolutionizing how we understand and treat food intolerances. We are proud to partner with this leading institution to bring cutting-edge solutions to patients and are excited by the growing adoption of CellTolerance worldwide.

Read the full PR: https://hubs.la/Q03xmsBC0

07/08/2025

This study underscores the transformative role of probe-based confocal laser endomicroscopy ( ) in managing , key for assessing deep inflammation, barrier healing, predicting relapse & even guiding therapy response with molecular imaging. This advanced imaging technique provides real-time, cellular-level insights, shaping the future of how we deliver targeted and effective IBD care.

Learn more: https://hubs.la/Q03wfjg-0


Crohn's & Colitis Foundation

06/26/2025

The test can have a profound impact on a patient’s life based on the results. Dr. med. Kai Wiemer illustrates how one patient was thrilled to learn her strict diet was unnecessary, while another finally pinpointed a hidden soy intolerance.

Integrating this test provides the actionable data to streamline your workflow and achieve better patient outcomes. Adopt a new, revolutionary approach to management: https://hubs.la/Q03tRyY80

06/24/2025

A groundbreaking preclinical study in Pharmaceuticals MDPI demonstrates the potential of for the intraoperative visualization of prostate cancer at a cellular resolution. By providing surgeons with real-time, in vivo histological data, this technology (NIR-pCLE) aims to enhance surgical accuracy and refine the delineation of tumor margins. Get ready for a new era in prostate cancer treatment.

Learn more: https://hubs.la/Q03tc59p0

06/19/2025

Offer your patients a more precise diagnosis, not educated guesses. The Program revolutionizes food intolerance management by revealing cellular-level gut reactions to food in real-time, enabling a multi-disciplinary team to translate those findings into a personalized, effective diet for struggling patients.

Position your practice at the forefront of digestive health innovation. Partner with CellTolerance: https://hubs.la/Q03sTjW-0